242 related articles for article (PubMed ID: 26709902)
1. Alternative mechanisms of inhibiting activity of poly (ADP-ribose) polymerase-1.
Sriram CS; Jangra A; Bezbaruah BK; V AK; Sykam S
Front Biosci (Schol Ed); 2016 Jan; 8(1):123-8. PubMed ID: 26709902
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
Virág L; Szabó C
Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) polymerase inhibitors.
Southan GJ; Szabó C
Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
[TBL] [Abstract][Full Text] [Related]
4. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
Komjáti K; Besson VC; Szabó C
Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Virág L
Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
[TBL] [Abstract][Full Text] [Related]
7. Role of Peroxynitrite-Induced Activation of Poly(ADP-Ribose) Polymerase (PARP) in Circulatory Shock and Related Pathological Conditions.
Islam BU; Habib S; Ali SA; Moinuddin ; Ali A
Cardiovasc Toxicol; 2017 Oct; 17(4):373-383. PubMed ID: 27990620
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation.
Erdélyi K; Bakondi E; Gergely P; Szabó C; Virág L
Cell Mol Life Sci; 2005 Apr; 62(7-8):751-9. PubMed ID: 15868400
[TBL] [Abstract][Full Text] [Related]
9. Natural inhibitors of poly(ADP-ribose) polymerase-1.
Banasik M; Stedeford T; Strosznajder RP
Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
[TBL] [Abstract][Full Text] [Related]
10. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention.
Virág L; Szabó E; Gergely P; Szabó C
Toxicol Lett; 2003 Apr; 140-141():113-24. PubMed ID: 12676457
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
12. The role of poly(ADP-ribose) polymerase-1 in CNS disease.
Kauppinen TM; Swanson RA
Neuroscience; 2007 Apr; 145(4):1267-72. PubMed ID: 17084037
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection.
Skaper SD
Ann N Y Acad Sci; 2003 May; 993():217-28; discussion 287-8. PubMed ID: 12853316
[TBL] [Abstract][Full Text] [Related]
14. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
[TBL] [Abstract][Full Text] [Related]
15. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.
Decker P; Muller S
Curr Pharm Biotechnol; 2002 Sep; 3(3):275-83. PubMed ID: 12164482
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
17. Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death.
Virág L; Szabó C
FASEB J; 2001 Jan; 15(1):99-107. PubMed ID: 11149897
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
19. A Review of PARP-1 Inhibitors: Assessing Emerging Prospects and Tailoring Therapeutic Strategies.
Ramesh S; Almeida SD; Hammigi S; Radhakrishna GK; Sireesha G; Panneerselvam T; Vellingiri S; Kunjiappan S; Ammunje DN; Pavadai P
Drug Res (Stuttg); 2023 Nov; 73(9):491-505. PubMed ID: 37890514
[TBL] [Abstract][Full Text] [Related]
20. Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1.
Tao R; Kim SH; Honbo N; Karliner JS; Alano CC
J Cardiovasc Pharmacol; 2010 Dec; 56(6):659-68. PubMed ID: 20881608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]